To provide a method for treating human patient suffered with a cardiovascular disease selected from arrhythmia, variant-form and exercise-induced angina, and myocardial infarction, administrated with ranolazine administration to keep plasma ranolazine near minimum effective level without causing peak fluctuation.

A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependant binder to form a film that is mostly insoluble in aqueous media of pH4.5 and soluble in aqueous media of pH4.5. The formulation is suitable for ranolazine administration of twice a day and useful for controlling the rate of dissolution of ranolazine and to maintain the human plasma ranolazine level at 850-4,000 ng/mL.